127 related articles for article (PubMed ID: 10194840)
21. Tolerance and immunogenicity of the simultaneous administration of virosome hepatitis A and yellow fever vaccines.
Bovier PA; Althaus B; Glueck R; Chippaux A; Loutan L
J Travel Med; 1999 Dec; 6(4):228-33. PubMed ID: 10575170
[TBL] [Abstract][Full Text] [Related]
22. Immunogenicity and adverse effects of inactivated virosome versus alum-adsorbed hepatitis A vaccine: a randomized controlled trial.
Holzer BR; Hatz C; Schmidt-Sissolak D; Glück R; Althaus B; Egger M
Vaccine; 1996 Jul; 14(10):982-6. PubMed ID: 8873392
[TBL] [Abstract][Full Text] [Related]
23. Efficient delivery of DNA to dendritic cells mediated by influenza virosomes.
Cusi MG; Terrosi C; Savellini GG; Di Genova G; Zurbriggen R; Correale P
Vaccine; 2004 Jan; 22(5-6):735-9. PubMed ID: 14741166
[TBL] [Abstract][Full Text] [Related]
24. Immune-reconstituted influenza virosome containing CD40L gene enhances the immunological and protective activity of a carcinoembryonic antigen anticancer vaccine.
Cusi MG; Del Vecchio MT; Terrosi C; Savellini GG; Di Genova G; La Placa M; Fallarino F; Moser C; Cardone C; Giorgi G; Francini G; Correale P
J Immunol; 2005 Jun; 174(11):7210-6. PubMed ID: 15905566
[TBL] [Abstract][Full Text] [Related]
25. Clinical immunogenicity and tolerance studies of liquid vaccines delivered by jet-injector and a new single-use cartridge (Imule): comparison with standard syringe injection. Imule Investigators Group.
Parent du Châtelet I; Lang J; Schlumberger M; Vidor E; Soula G; Genet A; Standaert SM; Saliou P
Vaccine; 1997 Mar; 15(4):449-58. PubMed ID: 9141217
[TBL] [Abstract][Full Text] [Related]
26. Efficient induction of tumoricidal cytotoxic T lymphocytes by HLA-A0201 restricted, melanoma associated, L(27)Melan-A/MART-1(26-35) peptide encapsulated into virosomes in vitro.
Schumacher R; Amacker M; Neuhaus D; Rosenthal R; Groeper C; Heberer M; Spagnoli GC; Zurbriggen R; Adamina M
Vaccine; 2005 Dec; 23(48-49):5572-82. PubMed ID: 16165256
[TBL] [Abstract][Full Text] [Related]
27. Influenza virosomes as a combined vaccine carrier and adjuvant system for prophylactic and therapeutic immunizations.
Moser C; Amacker M; Kammer AR; Rasi S; Westerfeld N; Zurbriggen R
Expert Rev Vaccines; 2007 Oct; 6(5):711-21. PubMed ID: 17931152
[TBL] [Abstract][Full Text] [Related]
28. Influenza virosomes: combining optimal presentation of hemagglutinin with immunopotentiating activity.
Huckriede A; Bungener L; ter Veer W; Holtrop M; Daemen T; Palache AM; Wilschut J
Vaccine; 2003 Feb; 21(9-10):925-31. PubMed ID: 12547604
[No Abstract] [Full Text] [Related]
29. Mucosal delivery of a combination adjuvant comprising emulsified fine particles and LD-indolicidin enhances serological immunity to inactivated influenza virus.
Huang MH; Dai SH; Chong P
Microbes Infect; 2016 Nov; 18(11):706-709. PubMed ID: 27394146
[TBL] [Abstract][Full Text] [Related]
30. Intranasal hydroxypropyl-β-cyclodextrin-adjuvanted influenza vaccine protects against sub-heterologous virus infection.
Kusakabe T; Ozasa K; Kobari S; Momota M; Kishishita N; Kobiyama K; Kuroda E; Ishii KJ
Vaccine; 2016 Jun; 34(27):3191-3198. PubMed ID: 27160037
[TBL] [Abstract][Full Text] [Related]
31. Incorporation of LpxL1, a detoxified lipopolysaccharide adjuvant, in influenza H5N1 virosomes increases vaccine immunogenicity.
de Vries JJ; Bungener L; Ter Veer W; van Alphen L; van der Ley P; Wilschut J; Huckriede A
Vaccine; 2009 Feb; 27(6):947-55. PubMed ID: 19059296
[TBL] [Abstract][Full Text] [Related]
32. Preparation, characterization and immunological evaluation of alginate nanoparticles loaded with whole inactivated influenza virus: Dry powder formulation for nasal immunization in rabbits.
Dehghan S; Kheiri MT; Abnous K; Eskandari M; Tafaghodi M
Microb Pathog; 2018 Feb; 115():74-85. PubMed ID: 29223454
[TBL] [Abstract][Full Text] [Related]
33. Adjuvanted influenza vaccines.
Principi N; Esposito S
Hum Vaccin Immunother; 2012 Jan; 8(1):59-66. PubMed ID: 22252004
[TBL] [Abstract][Full Text] [Related]
34. Bacterium-like particles supplemented with inactivated influenza antigen induce cross-protective influenza-specific antibody responses through intranasal administration.
de Haan A; Haijema BJ; Voorn P; Meijerhof T; van Roosmalen ML; Leenhouts K
Vaccine; 2012 Jul; 30(32):4884-91. PubMed ID: 22537989
[TBL] [Abstract][Full Text] [Related]
35. Virosomal adjuvanted antigen delivery systems.
Moser C; Metcalfe IC; Viret JF
Expert Rev Vaccines; 2003 Apr; 2(2):189-96. PubMed ID: 12899570
[TBL] [Abstract][Full Text] [Related]
36. A new and versatile virosomal antigen delivery system to induce cellular and humoral immune responses.
Kammer AR; Amacker M; Rasi S; Westerfeld N; Gremion C; Neuhaus D; Zurbriggen R
Vaccine; 2007 Oct; 25(41):7065-74. PubMed ID: 17766014
[TBL] [Abstract][Full Text] [Related]
37. Adjuvants for pandemic influenza vaccines.
Atmar RL; Keitel WA
Curr Top Microbiol Immunol; 2009; 333():323-44. PubMed ID: 19768413
[TBL] [Abstract][Full Text] [Related]
38. Immunogenicity, protective efficacy and mechanism of novel CCS adjuvanted influenza vaccine.
Even-Or O; Samira S; Rochlin E; Balasingam S; Mann AJ; Lambkin-Williams R; Spira J; Goldwaser I; Ellis R; Barenholz Y
Vaccine; 2010 Sep; 28(39):6527-41. PubMed ID: 20412874
[TBL] [Abstract][Full Text] [Related]
39. Oral vaccination with a liposome-encapsulated influenza DNA vaccine protects mice against respiratory challenge infection.
Liu J; Wu J; Wang B; Zeng S; Qi F; Lu C; Kimura Y; Liu B
J Med Virol; 2014 May; 86(5):886-94. PubMed ID: 24122866
[TBL] [Abstract][Full Text] [Related]
40. Intranasal inoculate of influenza virus vaccine against lethal virus challenge.
Fan X; Su Q; Qiu F; Yi Y; Shen L; Jia Z; Liang P; Zou Y; Bi S
Vaccine; 2018 Jul; 36(29):4354-4361. PubMed ID: 29880240
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
